Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10512609 Formulations of (R)-2-amino-3-phenylpropyl carbamate

Patent 10512609 was granted and assigned to Jazz Pharmaceuticals on December, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Current Assignee

Jazz Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

December 24, 2019

Patent Application Number

16225890

Date Filed

December 19, 2018

Patent Citations Received

US Patent 12128021 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

0

US Patent 12115144 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

0

US Patent 12115145 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

0

US Patent 11504347 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

US Patent 11583510 Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

US Patent 11602512 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

US Patent 11602513 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

US Patent 11766418 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

...

Patent Primary Examiner

Patent abstract

The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10512609 Formulations of (R)-2-amino-3-phenylpropyl carbamate

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.